Dr. Prasad Devarajan on NGAL

By On 30. January 2012 · Leave a Comment · In BioPorto

Dr. Devarajan has made a more comprehensive explanation of the nature of NGAL , the presentation is from 2010 – and since then Alere (Biosite) and Abbott has brought their test to the market.


Please note the cutoff-value mentioned (100) and bear in mind that you will find healthy individuals up to 146 (upper quartil), the presentation mentions 75 ng/ml as the “normal” value, and please taken in consideration that individuals who have inflammations or cancer can have signinficantly higher values – without their kidney being distressed—

http://www.slideshare.net/ringer21/emerging-biomarkers-of-aki

About Stengaard

BioPorto investor from way back when... I've invested in BioPorto ever since they made their debut on the danish stock exchange, it been a looooong journey with many obstacles. But well worth it all if Bioporto maintains their patent after the proceedings in 2014, and enters into agreements with Global Distributors in 2012 and 2013 If not, then it'll take another xx.years 🙂

Related posts:

  1. NGAL rises are seen in cancer-patients As mentioned in the MedicoInvestor Presentation NGAL for Dummies, Inflammation...
Tagged with: • • • •
 

Leave a Reply

Your email address will not be published. Required fields are marked *

Set your Twitter account name in your settings to use the TwitterBar Section.